Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge
Halozyme Therapeutics is entering a powerful earnings inflection, driven by surging royalty revenue and strategic acquisitions expanding its drug delivery platform. FY25 revenue grew 38% to $1.397 billion, with royalty revenue up 52%; recent acquisitions extend IP life and diversify the technology portfolio. 2026 guidance targets $1.71–$1.81 billion in revenue, over 70% EBITDA growth, and nearly 100% EPS growth, highlighting operating leverage and platform scalability.
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $2.15. This compares to earnings of $1.26 per share a year ago.
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
